CoChat
Sign Up
Cited by 117

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications

Olivieri, Fabiola, Spazzafumo, Liana, Bonafè, Massimiliano, Recchioni, Rina, Prattichizzo, Francesco, Marcheselli, Fiorella, Micolucci, Luigina, Mensà, Emanuela, Giuliani, Angelica, Santini, Gabriele, Gobbi, Mirko, Lazzarini, Raffaella, Boemi, Massimo, Testa, Roberto, Antonicelli, Roberto, Procopio, Antonio Domenico, Bonfigli, Anna Rita·2015·Oncotarget
DOI 10.18632/oncotarget.6164PMC PMC4742111
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6164

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Circulating levels of miR-21-5p and miR-126-3p in CTR subjects and T2DM patients Linear trend for miR-126-3p, F = 9.51, p = 0.002; linear trend for miR-21-5p: F = 5.33, p = 0.02. CTR: healthy control subjects; T2DM NC: patients without diabetic complications; T2DM C: patients with diabetic complications. RE = relative expression. Dotted line shows the exponential trend.
Figure 1 Circulating levels of miR-21-5p and miR-126-3p in CTR subjects and T2DM patients Linear trend for miR-126-3p, F = 9.51, p = 0.002; linear trend for miR-21-5p: F = 5.33, p = 0.02. CTR: healthy control subjects; T2DM NC: patients without diabetic complications; T2DM C: patients with diabetic complications. RE = relative expression. Dotted line shows the exponential trend.CC BY · PubMed Central
Figure 2 Overview of diabetic patients without or with complications A. Venn diagramm showing the overlaps between different complications (T2DMC). B. Histogram displaying the size of each group of T2DM. C. Charts showing number of T2DM patients without complications and with one or more complications.
Figure 2 Overview of diabetic patients without or with complications A. Venn diagramm showing the overlaps between different complications (T2DMC). B. Histogram displaying the size of each group of T2DM. C. Charts showing number of T2DM patients without complications and with one or more complications.CC BY · PubMed Central
Figure 3 Circulating levels of miR-21-5p and miR-126-3p in CTR and T2DM patients CTR: healthy control subjects; T2DM NC: patients without diabetic complications; T2DM C: patients with diabetic complications; RE = relative expression; MACE: T2DM patients with a previous MACE; MACE+OC (other complications): T2DM patients with a previous MACE and at least another diabetic complication; OC (other complications): T2DM patients with complications other than MACE. RE: relative expression; CTR: healthy control subjects; NC: diabetic patients without diabetic complications; MACE: T2DM patients with a previous MACE; MACE+OC (other complications): T2DM patients with a previous MACE and at least another diabetic complication; OC (other complications): patients with diabetic complications other than MACE. MiR-21-5p: ANCOVA adjusted for age, sex, BMI, glucose, and HbA1c; F-test = 6.44, p < 0.001; ANCOVA adjusted for age and sex; F-test = 8.375, p < 0.001. MiR-126-3p: ANCOVA adjusted for age, sex, glucose, and HbA1c; F-test = 4.55, p = 0.01; miR-126-3p: ANCOVA adjusted for age and sex; F-test = 6.655, p = 0.002. #Bonferroni's correction, alpha = 0.05/10, p < 0.005, reference group: T2DM NC; *Bonferroni's correction, alpha = 0.05/10, p < 0.005, reference group: CTR.
Figure 3 Circulating levels of miR-21-5p and miR-126-3p in CTR and T2DM patients CTR: healthy control subjects; T2DM NC: patients without diabetic complications; T2DM C: patients with diabetic complications; RE = relative expression; MACE: T2DM patients with a previous MACE; MACE+OC (other complications): T2DM patients with a previous MACE and at least another diabetic complication; OC (other complications): T2DM patients with complications other than MACE. RE: relative expression; CTR: healthy control subjects; NC: diabetic patients without diabetic complications; MACE: T2DM patients with a previous MACE; MACE+OC (other complications): T2DM patients with a previous MACE and at least another diabetic complication; OC (other complications): patients with diabetic complications other than MACE. MiR-21-5p: ANCOVA adjusted for age, sex, BMI, glucose, and HbA1c; F-test = 6.44, p < 0.001; ANCOVA adjusted for age and sex; F-test = 8.375, p < 0.001. MiR-126-3p: ANCOVA adjusted for age, sex, glucose, and HbA1c; F-test = 4.55, p = 0.01; miR-126-3p: ANCOVA adjusted for age and sex; F-test = 6.655, p = 0.002. #Bonferroni's correction, alpha = 0.05/10, p < 0.005, reference group: T2DM NC; *Bonferroni's correction, alpha = 0.05/10, p < 0.005, reference group: CTR.CC BY · PubMed Central
Figure 4 MiR-21-5p and miR-126-3p expression levels in CACs from CTR, T2DM NC and T2DM +MACE patients T2DM NC: patients without diabetic complications; T2DM + MACE: T2DM patients with a previous MACE; RE = relative expression.
Figure 4 MiR-21-5p and miR-126-3p expression levels in CACs from CTR, T2DM NC and T2DM +MACE patients T2DM NC: patients without diabetic complications; T2DM + MACE: T2DM patients with a previous MACE; RE = relative expression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 41

  1. Karter, 2014, Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study, JAMA Intern Med, 174, 251, 10.1001/jamainternmed.2013.12956 · DOI · Paper page
  2. Emanueli, 2014, Noncoding RNAs in diabetes vascular complications, J Mol Cell Cardiol, 10.1016/j.yjmcc.2014.12.014 · DOI
  3. Béguinot, 2015, Understanding type 2 diabetes: from genetics to epigenetics, ActaDiabetol, 52, 821, 10.1007/s00592-015-0741-0 · DOI
  4. Ji, 2015, Serum metabolite signatures of type 2 diabetes mellitus complications, J Proteome Res, 14, 447, 10.1021/pr500825y · DOI
  5. Natarajan, 2015, Epigenetic mechanisms in diabetic complications and metabolic memory, Diabetologia, 58, 443, 10.1007/s00125-014-3462-y · DOI
  6. Roberts, 2014, The MicroRNA Biology of the Mammalian Nucleus, Mol Ther Nucleic Acids, 3, e188, 10.1038/mtna.2014.40 · DOI
  7. Camussi, 2010, Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs, PLoS One, 5, e11803, 10.1371/journal.pone.0011803 · DOI · Paper page
  8. Weber, 2009, Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection, Sci Signal, 2, ra81, 10.1126/scisignal.2000610 · DOI
  9. Remaley, 2011, MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins, Nat Cell Biol, 13, 423, 10.1038/ncb2210 · DOI · Paper page
  10. Tewari, 2011, Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma, Proc Natl Acad Sci U S A, 108, 5003, 10.1073/pnas.1019055108 · DOI · Paper page
  11. Burwinkel, 2011, Characterization of extracellular circulating microRNA, Nucleic Acids Res, 39, 7223, 10.1093/nar/gkr254 · DOI · Paper page
  12. Burwinkel, 2012, Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma, RNA Biol, 9, 1066, 10.4161/rna.21083 · DOI · Paper page
  13. Leung, 2015, Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies, Diabetologia, 58, 900, 10.1007/s00125-015-3510-2 · DOI
  14. Prokopi, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ Res, 107, 810, 10.1161/CIRCRESAHA.110.226357 · DOI · Paper page
  15. Jiang, 2014, The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus, Int J Mol Sci, 15, 10567, 10.3390/ijms150610567 · DOI · Paper page
  16. Su, 2013, Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals, Biomed Res Int, 2013, 761617, 10.1155/2013/761617 · DOI
  17. Werner, 2014, MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease, J Am Heart Assoc, 3, e001249, 10.1161/JAHA.114.001249 · DOI
  18. Brizzi, 2015, Unacylated ghrelin induces oxidative stress resistance in a glucose intolerance and peripheral artery disease mouse model by restoring endothelial cell miR-126 expression, Diabetes, 64, 1370, 10.2337/db14-0991 · DOI
  19. Wang, 2012, Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties,target gene Spred-1, J Mol Cell Cardiol, 53, 64, 10.1016/j.yjmcc.2012.04.003 · DOI
  20. Thum, 2011, Regulation and function of miRNA-21 in health and disease, RNA Biol, 8, 706, 10.4161/rna.8.5.16154 · DOI
  21. Montgomery, 2014, Effect of aging on microRNAs and regulation of pathogen recognition receptors, Curr Opin Immunol, 29, 29, 10.1016/j.coi.2014.03.006 · DOI
  22. Franceschi, 2013, MicroRNAs linking inflamm-aging, cellular senescence and cancer, Ageing Res Rev, 12, 1056, 10.1016/j.arr.2013.05.001 · DOI
  23. Li, 2013, miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes, Diabetologia, 56, 663, 10.1007/s00125-012-2804-x · DOI
  24. Da Costa Martins, 2015, miR-21: a star player in cardiachypertrophy, Cardiovasc Res, 105, 235, 10.1093/cvr/cvv026 · DOI
  25. Zhang, 2014, Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction, Mol Med Rep, 10, 971, 10.3892/mmr.2014.2245 · DOI
  26. Antonicelli, 2013, Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs, Biomarkers, 18, 547, 10.3109/1354750X.2013.833294 · DOI
  27. van Zonneveld, 2013, Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease, Eur Heart J, 34, 3451, 10.1093/eurheartj/eht007 · DOI
  28. Procopio, 2013, Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction, Int J Cardiol, 167, 531, 10.1016/j.ijcard.2012.01.075 · DOI
  29. Wang, 2014, Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction, PLoS One, 9, e105734, 10.1371/journal.pone.0105734 · DOI
  30. Pompilio, 2013, Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina, PLoSOne, 8, e80345, 10.1371/journal.pone.0080345 · DOI
  31. Li, 2014, microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosisthe phosphatase and tensin homolog/Akt-dependent mechanism, Mol Med Rep, 9, 2213, 10.3892/mmr.2014.2068 · DOI
  32. Shen, 2013, Ischemic postconditioning-mediated miRNA-21 protects against cardiac ischemia/reperfusion injuryPTEN/Akt pathway, PLoS One, 8, e75872, 10.1371/journal.pone.0075872 · DOI
  33. He, 2015, MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGFβ signaling pathwaydownregulation of WWP1, Int J Clin Exp Pathol, 8414
  34. Wieser, 2013, High levels of oncomiR-21 contribute to the senescence-induced growth arrest in normal human cells and its knock-down increases the replicative lifespan, Aging Cell, 12, 446, 10.1111/acel.12069 · DOI
  35. Habeos, 2012, Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice, PLoS One, 7, e34872, 10.1371/journal.pone.0034872 · DOI
  36. Brizzi, 2015, Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical applications, Int J Obes (Lond), 10.1038/ijo.2015.123 · DOI
  37. Tao, 2013, MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis, Exp Clin Endocrinol Diabetes, 121, 425, 10.1055/s-0033-1345169 · DOI
  38. Procopio, 2013, Telomere/telomerase system impairment in circulating angiogenic cells of geriatric patients with heart failure, Int J Cardiol, 164, 99, 10.1016/j.ijcard.2011.06.091 · DOI
  39. Procopio, 2011, Leukocyte telomere length is associated with complications of type 2 diabetes mellitus, Diabet Med, 28, 1388, 10.1111/j.1464-5491.2011.03370.x · DOI
  40. Olivieri, 2015, Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes, Clin Epigenetics, 7, 56, 10.1186/s13148-015-0090-4 · DOI
  41. Olivieri, 2015, Endothelial cell senescence and inflammaging: microRNAs as biomarkers and innovative therapeutic tools, Curr Drug Targets

Cited by

Sorted by citations

Metadata

Authors
Olivieri, F., Spazzafumo, L., Bonafè, M., Recchioni, R., Prattichizzo, F., Marcheselli, F., Micolucci, L., Mensà, E., Giuliani, A., Santini, G., Gobbi, M., Lazzarini, R., Boemi, M., Testa, R., Antonicelli, R., Procopio, A. D., & Bonfigli, A. R.
Affiliations
  • Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
  • Center of Biostatistics, INRCA-IRCCS National Institute, Ancona, Italy
  • Department of Experimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna, Bologna, Italy
  • Center of Clinical Pathology and Innovative Therapy, INRCA-IRCCS National Institute, Ancona, Italy
  • Metabolic Diseases and Diabetology Unit, INRCA-IRCCS National Institute, Ancona, Italy
  • Experimental Models in Clinical Pathology, INRCA-IRCCS National Institute, Ancona, Italy
  • UTIC-Cardiology Unit, INRCA-IRCCS National Institute, Ancona, Italy
  • Scientific Direction, INRCA-IRCCS, National Institute, Ancona, Italy
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2015-10-19
Volume
6
Issue
34
Pages
35372-35382
ISSN
1949-2553
DOI
10.18632/oncotarget.6164
PMC
PMC4742111
Cited by
117
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review